Interleukin-8 receptor antagonists in pulmonary diseases.
Inflammatory cells are thought to be instrumental in the pathophysiology of pulmonary diseases, and control of their recruitment and activation in the lung would appear to be an attractive strategy for therapeutic intervention. Interleukin-8 and related CXC chemokines are involved in the function of neutrophils and T cells, and have been implicated in several lung diseases. Small-molecule antagonists of the interleukin-8 receptors have been identified, which may help elucidate the role of interleukin-8 and related chemokines in the pathophysiology of lung diseases.
Hay
D W
DW
Respiratory, Inflammation and Respiratory Pathogens Center for Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA 19406, USA. douglas_w_hay@sbphrd.com
Sarau
H M
HM
D000818:Animals; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism / Q000502:physiology*; D008171:Lung Diseases / Q000188:drug therapy*; D023062:Receptors, Interleukin-8A / Q000037:antagonists & inhibitors* / Q000502:physiology
D016209:Interleukin-8; D023062:Receptors, Interleukin-8A